# EDGAR Filing Document

**Accession Number:** 0001326205
**File Stem:** 0001185185-26-002410
**Filing Date:** 2026-6
**Character Count:** 6831
**Document Hash:** b761370196b2d6d8e187286f27f01934
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001185185-26-002410.hdr.sgml**: 20260608

**ACCESSION NUMBER**: 0001185185-26-002410

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 46

**CONFORMED PERIOD OF REPORT**: 20260605

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260608

**DATE AS OF CHANGE**: 20260608

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IGC Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001326205
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 202760393
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32830
- **FILM NUMBER:** 261072540

**BUSINESS ADDRESS:**
- **STREET 1:** 10224 FALLS ROAD
- **CITY:** POTOMAC
- **STATE:** MD
- **ZIP:** 20854
- **BUSINESS PHONE:** 301-529-4996

**MAIL ADDRESS:**
- **STREET 1:** 10224 FALLS ROAD
- **CITY:** POTOMAC
- **STATE:** MD
- **ZIP:** 20854

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** India Globalization Capital, Inc.
- **DATE OF NAME CHANGE:** 20050505

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **<u>June 5, 2026</u>**

![](image_001.jpg)

**<u>IGC PHARMA, INC.</u>**

(Exact name of registrant as specified in charter)

---

| | | |
|:---|:---|:---|
| **Maryland** | **001-32830** | **20-2760393** |
| (State or other jurisdiction <br> of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**<u>10224 Falls Road, Potomac, Maryland 20854</u>**

(Address of principal executive offices) (Zip Code)

**<u>(301) 983-0998</u>**

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, $.0001 par value IGC | NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement**

***Extension of Master Loan and Security Agreement***

On June 5, 2026, IGC Pharma, Inc. ("IGC" or the "Company") entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter (collectively, the "Loan Agreement") with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender (the "Lender").

The Loan Agreement continues the facility arrangement previously set forth in the General Banking Facility Letter dated June 24, 2025. The facility provides for a maximum aggregate limit of $12,000,000. The material terms of the facility remain substantially unchanged from the 2025 facility letter, except that the facility fee has increased from $48,000 to $60,000.

The foregoing summary of the Loan Agreement is qualified in its entirety by reference to the full text of the Loan Agreement, a copy of which is filed hereto as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The information set forth in Item 1.01 is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1\* | [2026 O-Bank General Banking Facility Letter.](igcex10-1.htm) |
| 10.2\* | [2025 O-Bank General Banking Facility Letter (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 14, 2025).](igcex10-2.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |

---

\* Certain schedules or similar attachments to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.

The registrant hereby agrees to furnish supplementally to the Securities and Exchange Commission upon request a copy of any omitted schedule or attachment to this exhibit.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **IGC Pharma, Inc.** | **IGC Pharma, Inc.** | **IGC Pharma, Inc.** |
| Dated: June 8, 2026 |  |  |  |
|  | By: | /s/ Ram Mukunda | /s/ Ram Mukunda |
|  |  | Name: | Ram Mukunda |
|  |  | Title: | CEO |

---

## Exhibit 10.1

**Exhibit 10.1**

![](ex10-1_001.jpg)

![](ex10-1_002.jpg)

![](ex10-1_003.jpg)

![](ex10-1_004.jpg)

![](ex10-1_005.jpg)

![](ex10-1_006.jpg)

![](ex10-1_007.jpg)

![](ex10-1_008.jpg)

![](ex10-1_009.jpg)

![](ex10-1_010.jpg)

![](ex10-1_011.jpg)

![](ex10-1_012.jpg)

![](ex10-1_013.jpg)

![](ex10-1_014.jpg)

![](ex10-1_015.jpg)

![](ex10-1_016.jpg)

## Exhibit 10.2

**Exhibit 10.2**

![](ex10-2_001.jpg)

![](ex10-2_002.jpg)

![](ex10-2_003.jpg)

![](ex10-2_004.jpg)

![](ex10-2_005.jpg)

![](ex10-2_006.jpg)

![](ex10-2_007.jpg)

![](ex10-2_008.jpg)

![](ex10-2_009.jpg)

![](ex10-2_010.jpg)

![](ex10-2_011.jpg)

![](ex10-2_012.jpg)

![](ex10-2_013.jpg)

![](ex10-2_014.jpg)

![](ex10-2_015.jpg)

![](ex10-2_016.jpg)